FDA advisory panel unanimously votes to approve dissolvable heart stent

A panel of Food and Drug Administration advisors has unanimously backed the safety and effectiveness of an experimental cardiac stent that dissolves two to three years after implantation, according to Reuters.

Advertisement

The stent is developed by Abbott Laboratories and made of a degradable material that dissipates much like stitches after a year for patients who have had their arteries cleared of plaque. The new device could be a good alternative to metal stents, which in rare instances break and cause serious complications.

Although trials of the new stent haven’t produced statistically significant improvements in patient outcomes, the device could receive FDA approval by year’s end. 

More articles on quality:

Patent application suggests Apple Watch could become medical device
Physicians call on Congress to crack down on wound care product managers
Study: Disruptive patients more likely to receive misdiagnosis

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

When nurses help build the AI, adoption follows: Lessons from 3 health systems

Tuesday, July 28
11:00 AM - 12:00 PM CDT

Presenters: Amy McCarthy, DNP, RNC-MNN, NE-BC, CENP, Hippocratic AIBeth Reimschissel, PhD, RN, CNL, Memorial HermannAllison Schlinkert, MSN, RN, NPD-BC, Cincinnati Children'sScott Estep, MBOE, BSN, RN, CSSBB, OhioHealth System

Advertisement

Next Up in Clinical Leadership & Infection Control

Advertisement

Comments are closed.